Science & evidence
One chemical class, an immune-restricted target, and completed in vivo proof of concept
Azalla’s two compounds share a common scaffold, a common CB2 mechanism and a common chemistry, formulation and manufacturing base. Both have been characterized in cell-based assays and tested in the same live disease model.
The target
Why CB2
CB2 is a cannabinoid receptor expressed almost exclusively on immune cells and not present in the brain at meaningful levels. Engaging it tells activated immune cells to stand down, which is the basis of the anti-inflammatory effect — and because the receptor is immune-restricted, the effect stays peripheral.
Selectivity over CB1 is what keeps it there. J-041 is selective for CB2 over CB1 by a margin we have quantified, so the mechanism avoids the central nervous system effects associated with cannabinoid compounds that act on CB1.
J-019 adds a second, independently confirmed mechanism. PPARγ is a nuclear receptor with an established role in resolving inflammation and protecting nerve tissue inside the central nervous system — relevant precisely where an MS therapy needs to act.
The chemistry
A shared scaffold
Both compounds derive from a single proprietary chemical class. That means a shared synthetic route, shared analytical methods, a shared formulation and a shared manufacturing base, executed by the same partners under the same protocols.
Each compound still carries its own regulatory toxicology package — that work cannot be shared. But the platform work behind both is done once, which is what allows a company of our size to run two candidates rather than choosing between them.
- J-041
- Full CB2 agonist, selective over CB1
- J-019
- CB2 agonist with confirmed PPARγ activity
- Shared platform
- Analytical methods, formulation and CMC route established
Proof of concept
Efficacy in a live disease model against an active steroid
Both compounds were evaluated in a standard, well-characterized autoimmune inflammation model, dosed once daily over a multi-week course and scored by an independent contract research organization. A potent corticosteroid was set as the active comparator rather than vehicle alone.
Relative disease severity over the dosing period; lower is better. Axis values withheld; shape shown for illustration. Source: An independent contract research organization.
No significant separation from the steroid
At its efficacious dose, J-041 showed no statistically significant difference from the corticosteroid comparator at any measurement timepoint — the only test arm to hold that position for the full study. The steroid remained numerically lower at the terminal endpoint.
Significant on function, not just appearance
A functional endpoint, measured independently of visual disease scoring, improved significantly versus vehicle for both compounds, and none of those arms differed significantly from the corticosteroid comparator.
Dose-response confirmed in tissue and blood
A broad terminal cytokine panel showed dose-ordered reductions in TNF-α, IL-15, CXCL10 and CXCL9. Histopathology showed a significant dose-response in both limbs scored. At tissue level the steroid was superior at one site and statistically indistinguishable from J-041 at the other.
Two compounds, both significantly better than vehicle. The lead arm showed no significant separation from a potent steroid across the full dosing period.
Methodological note: histopathology to date is an internal unblinded read, statistically validated against two independent measurement systems with strong concordance. Blocks and slides are retained and a blinded re-read by a board-certified veterinary pathologist is scheduled. Clinical scoring reflects swelling while histology captures deeper tissue architecture, and both are reported.
Source: In vivo efficacy study conducted by an independent contract research organization.
Intellectual property
Independent composition-of-matter coverage on both compounds
Each asset sits on its own composition-of-matter estate — the second compound is protected in its own right, not as a dependent claim of the first. Coverage extends to formulations and methods of use, is filed in the major commercial territories, and is prosecuted by specialist intellectual property counsel with all deadlines and annuities managed on an active docket.
- Composition of matter, formulations and methods of use for the lead dermatomyositis compound.
- Filed in the major commercial territories, with international applications preserving further national entry.
- Actively prosecuted; all deadlines and annuities current.
- Composition of matter, formulations and methods of use for the multiple sclerosis compound.
- Filed on the same territorial footprint as the lead asset.
- Independent coverage: the second asset is protected on its own estate, not as a dependent claim of the first.
Application numbers, claim scope, filing dates and territory-by-territory status are not published here. The full patent schedule is provided to partners and prospective investors under a confidentiality agreement.
Talk to us about the programs
Scientific, partnering, clinical, media and corporate inquiries all come through one form and are read by the people running the program.